Biovail Corp said it was voluntarily recalling certain lots of Ultram tablets, its treatment for chronic pain in adults, and expects the total cost related to the recall to hurt fourth-quarter Ultram revenues by $4.4 million.
Biovail voluntarily recalls some lots of Ultram tablets